PDCD1 and alveolar soft part sarcoma: Regardless of the underlying mechanism of sensitivity, the available evidence provides a clear signal of the activity of anti-PD1 or anti-PD-L1 therapy in ASPS and ongoing clinical investigation of such treatments represent a highly promising therapeutic avenue for patients with this rare sarcoma subtype.